Study on drug costs associated with COPD prescription medicine in Denmark

Spirometric studies of the general population estimate that 430 000 Danes have chronic obstructive pulmonary disease (COPD). COPD is mainly caused by smoking, and smoking cessation is the most important intervention to prevent disease progression. Cost‐of‐illness studies conclude that the costs associated with COPD in Denmark are significant, but costs of prescription medicine for COPD were not analysed.

[1]  Anand A. Dalal,et al.  Economic burden of chronic bronchitis in the United States: a retrospective case-control study , 2011, International journal of chronic obstructive pulmonary disease.

[2]  J Vestbo,et al.  A 15-year follow-up study of ventilatory function in adults with asthma. , 1998, The New England journal of medicine.

[3]  Jack E. Triplett,et al.  Handbook on Hedonic Indexes and Quality Adjustments in Price Indexes: Special Application to Information Technology Products , 2006 .

[4]  A. Buist,et al.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study , 2009, European Respiratory Journal.

[5]  E. Wouters.  Economic analysis of the Confronting COPD survey: an overview of results. , 2003, Respiratory medicine.

[6]  K. R. Chapman,et al.  Epidemiology and costs of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[7]  J Vestbo,et al.  Developing COPD: a 25 year follow up study of the general population , 2006, Thorax.

[8]  Anand A. Dalal,et al.  Direct costs of chronic obstructive pulmonary disease among managed care patients , 2010, International journal of chronic obstructive pulmonary disease.

[9]  S. Borg,et al.  Costs of COPD in Sweden according to disease severity. , 2002, Chest.

[10]  S. Borg,et al.  Costs of COPD in Sweden according to disease severity. , 2007, Chest.

[11]  P. Lange,et al.  Validity and underrecording of diagnosis of COPD in the Danish National Patient Registry. , 2011, Respiratory medicine.

[12]  L. Mantovani,et al.  The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature , 2011, Current opinion in pulmonary medicine.

[13]  J. Vestbo,et al.  [Prevalence of chronic obstructive pulmonary disease in Copenhagen. Results from The Copenhagen City Heart Study]. , 2007, Ugeskrift for laeger.

[14]  K Larsson,et al.  Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2003, Respiratory medicine.

[15]  J. Dollerup,et al.  The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls. , 2007, Respiratory medicine.

[16]  J. de Miguel-Díez,et al.  Economic Impact of Pulmonary Drugs on Direct Costs of Stable Chronic Obstructive Pulmonary Disease , 2004 .

[17]  D. Mannino,et al.  Lifetime risk of COPD: what will the future bring? , 2011, The Lancet.

[18]  R. Pauwels,et al.  Burden and clinical features of chronic obstructive pulmonary disease (COPD) , 2004, The Lancet.

[19]  J. Vestbo,et al.  [Developing COPD--25 years follow-up study of the general population]. , 2006, Ugeskrift for laeger.

[20]  A. Briggs,et al.  Pharmacoeconomics in COPD: lessons for the future , 2008, International journal of chronic obstructive pulmonary disease.

[21]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[22]  Patrick Hagge Cording,et al.  Early detection of COPD in general practice , 2010, International journal of chronic obstructive pulmonary disease.